All In Biotech

NDA 050753 · Viatris

Tobi

Tobramycin · Inhalation · Aminoglycoside Antibacterial

Priority reviewOrphan

Last checked: Nov 19, 2026Latest source record: Feb 10, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1997

Dec 22, 1997

Approved uses

1

Original approval plus efficacy supplements

Registered trials

144

50 Phase 3, 6 recruiting

FAERS reports

17,580

14,064 serious, 2,372 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 15, 2025.

TOBI is indicated for the management of cystic fibrosis in adults and pediatric patients 6 years of age and older with Pseudomonas aeruginosa . Safety and efficacy have not been demonstrated in patients under the age of 6 years, patients with forced expiratory volume in 1 second (FEV 1 ) < 25% or > 75% predicted, or patients colonized with Burkholderia cepacia [see Clinical Studies (14) ]. TOBI is an aminoglycoside antibacterial indicated for the management of cystic fibrosis in adults and pediatric patients 6 years of age and older with Pseudomonas aeruginosa . ( 1 ) Safety and efficacy have not been demonstrated in patients under the age of 6 years, patients with forced expiratory volume in 1 second (FEV 1 ) < 25% or > 75% predicted, or patients colonized with Burkholderia cepacia. ( 1 )

Mechanism: Tobramycin is an aminoglycoside antibacterial [see Microbiology (12.4) ] . Mechanism of Action Tobramycin is an aminoglycoside antibacterial produced by Streptomyces tenebrarius . (1) It acts primarily by disrupting protein synthesis, leading to altered cell membrane permeability, progressive disruption of the cell envelope, and eventual cell death. (3) Tobramycin has in vitro activity against gram-negative bacteria including Pseudomonas aeruginosa . It is bactericidal in vitro at concentrations equal to or slightly greater than the minimum inhibitory concentration (MIC).

Therapeutic areas: Infectious disease and vaccines

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 22, 1997 Original approval · Type 3 - New Dosage Form · priority review Review
1 products under this application
  • TOBI · TOBRAMYCIN 300MG/5ML · SOLUTION, INHALATION · Prescription · TE AN

Clinical trials

Interventional ClinicalTrials.gov studies with "Tobramycin" as an intervention, any sponsor and status, largest first.

All 144 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • death1,343
  • infective pulmonary exacerbation of cystic fibrosis1,134
  • pneumonia1,109
  • dyspnoea1,049
  • off label use1,044
  • cystic fibrosis830
  • cough813
  • drug ineffective781
  • acute kidney injury712
  • infection675
  • condition aggravated639
  • hospitalisation604

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200492
2005113
200692
2007146
2008117
2009132
2010193
2011716
2012685
2013720
2014786
20151,157
2016847
2017895
20181,449
20192,047
20201,652
20211,110
20221,045
2023881
20241,079
2025937
2026689

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Tobi (Tobramycin In 0.225% Sod Chlor)

2024 spending

$46K

Beneficiaries

n/a

11 claims

Per beneficiary

n/a

$30.33 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$148,702
2024$46,097

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 795 on PubMed

Sponsor: Viatris

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.